Thomas H. McLain Appointed to the Biotechnology Industry Organization's Board of Directors
Nabi Biopharmaceuticals (Nasdaq: NABI - News) announced today that its chairman, chief executive officer and president, Thomas H. McLain, has been appointed to the Board of Directors of the Biotechnology Industry Organization (BIO), effective June 21, 2005. Mr. McLain is one of eleven new Board members, who will each serve two-year terms. BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. "Biotechnology's impact on human health has never been greater; its discoveries are beginning to realize their great promise. I am honored to accept this Board position, as our industry continues to serve as a leading force in the advancement of 21st century medicine," said Mr. McLain. Mr. McLain joined Nabi Biopharmaceuticals in 1998 and today serves as chairman, chief executive officer and president of the company. >From 1988 to 1998, Mr. McLain was employed by Bausch & Lomb, Incorporated. He earned his B.A. in Economics at College of the Holy Cross and an M.B.A. from the William E. Simon Graduate School of Business at the University of Rochester. He is a member of the Board of Directors of Eastman Chemical Company and serves as the Chairman of BioFlorida. "Tom McLain is a widely recognized leader in the emerging life sciences arena both nationally and internationally," said Florida Governor Jeb Bush. "As Florida is increasingly positioned at the epicenter of this industry, we are fortunate to have someone of Tom's caliber contributing on a national scale. I applaud BIO's decision to recognize Tom's commitment to and noted achievements in biotechnology, and look forward to his ongoing leadership to escort the industry to new heights." "Tom McLain's knowledge, experience and vision make him an ideal addition to our Board of Directors," said BIO President James Greenwood. "In particular, we value his expertise in vaccines and his role in the emergence of biotech in Florida." About Nabi Biopharmaceuticals Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. We are poised to capture large, commercial opportunities in our four core business areas: Gram- positive bacterial infections, hepatitis, kidney disease (nephrology), and nicotine addiction. We have three products on the market today: PhosLo® (calcium acetate), Nabi-HB® [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium (for injection)] and a number of products in various stages of clinical and preclinical development. The company filed its Marketing Authorization Application in Europe for its product candidate, StaphVAX® [Staphylococcus aureus Polysaccharide Conjugate Vaccine], in December 2004. The application was accepted for review in January 2005. StaphVAX is currently in a confirmatory Phase III clinical trial in the U.S. StaphVAX is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. S. aureus bacteria are a major cause of hospital-acquired infections and are becoming increasingly resistant to antibiotics. The company's other products in development include Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an antibody for prevention and treatment of S. aureus infections, NicVAX (TM) [Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing hepatitis C virus re-infection in liver transplant patients. For additional information on Nabi Biopharmaceuticals, please visit our website at: http://www.nabi.com . This press release contains forward-looking statements that reflect the company's current expectations regarding future events. Any such forward- looking statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may differ significantly from those in the forward-looking statements as a result of any number of factors, including, but not limited to, risks relating to the possibility that our confirmatory Phase III clinical trial for StaphVAX or our plans to commercialize StaphVAX in the European Union and United States may not be successful; the possibility that we may not realize the value of our acquisition of PhosLo; the company's ability to raise additional capital on acceptable terms; the company's dependence upon third parties to manufacture its products; the company's ability to utilize the full capacity of its manufacturing facility; the impact on sales of Nabi- HB from patient treatment protocols and the number of liver transplants performed in HBV-positive patients; reliance on a small number of customers; the future sales growth prospects for the company's biopharmaceutical products; and the company's ability to obtain regulatory approval for its products in the United States or abroad or to successfully develop, manufacture and market its products. These factors are more fully discussed in the company's Annual Report on Form 10-K for the fiscal year ended December 25, 2004 filed with the Securities and Exchange Commission. --------------------------------------------------------------------- ----------- Source: Nabi Biopharmaceuticals http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/index.php http://www.arizonabiotech.com/ <a href="http://www.arizonabiotech.com/";>Arizona Biotech</a> http://groups.yahoo.com/group/biotech-news/ <a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a> http://www.arizonaentrepreneurs.com/ <a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a> http://www.azhttp.com/ <a href="http://www.azhttp.com/";>Arizona High Tech</a> Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
